Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events

    April 2025 in “ Biologics ”
    Simonetta I. Gaumond, Isabella Kamholtz, Joaquín J. Jiménez
    Studysummary This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on mdpi.com →
    Discuss this study in the Community →

    Research cited in this study 30

    1. Evaluation of Serum Inflammatory Markers and Their Relationship to Treatment Response in Alopecia Areata Patients Dermatology Practical & Conceptual · 2024
    2. Case Report: Sequential Therapy with Dupilumab and Baricitinib for Severe Alopecia Areata with Atopic Dermatitis in Children Frontiers in immunology · 2024
    3. Dupilumab Therapy for Alopecia Areata: A Case Series and Review of the Literature Journal of Dermatological Treatment · 2024
    4. Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2024
    5. Dupilumab Therapy for Alopecia Areata in a 4-Year-Old Patient Resistant to Baricitinib Frontiers in Medicine · 2023
    6. Biomarkers in Alopecia Areata: A Systematic Review and Meta-Analysis Autoimmunity reviews · 2023
    7. Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population JAMA Dermatology · 2023
    8. Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches Antioxidants · 2023
    9. Scalp Biomarkers During Dupilumab Treatment Support Th2 Pathway Pathogenicity in Alopecia Areata Allergy · 2022
    10. Morphogenesis, Growth Cycle, and Molecular Regulation of Hair Follicles Frontiers in Cell and Developmental Biology · 2022
    11. Alopecia Areata: Current Understanding and Management Journal der Deutschen Dermatologischen Gesellschaft · 2022
    12. Increased Serum Interleukin-17A Levels Correlate with Disease Severity and Poor Prognostic Factors in Patients with Alopecia Areata Dermatology Reports · 2021
    13. Dupilumab for the Treatment of Alopecia Areata in Children with Atopic Dermatitis JAAD case reports · 2021
    14. Treatment of Chronic Alopecia Areata With Tildrakizumab: An Open-Label Pilot Study International Journal of Dermatology · 2020
    15. Alopecia Areata in 2 Patients Treated with Dupilumab: New Onset and Worsening JAAD Case Reports · 2019
    16. Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity British journal of dermatology/British journal of dermatology, Supplement · 2019
    17. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report Acta Dermato Venereologica · 2019
    18. Drug-Induced Alopecia After Dupilumab Therapy JAAD case reports · 2018
    19. Response to Ustekinumab in Three Pediatric Patients with Alopecia Areata Pediatric dermatology · 2018
    20. The Eyelash Follicle Features and Anomalies: A Review Journal of optometry · 2018
    21. Effective Use of Ustekinumab in a Patient with Concomitant Psoriasis, Vitiligo, and Alopecia Areata JAAD case reports · 2017
    22. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
    23. Promotion of Anagen, Increased Hair Density, and Reduction of Hair Fall in a Clinical Setting Following Identification of FGF5-Inhibiting Compounds via a Novel 2-Stage Process Clinical, Cosmetic and Investigational Dermatology · 2017
    24. Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism The Journal of Allergy and Clinical Immunology · 2015
    25. Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2015
    26. Alopecia Universalis Successfully Treated With Adalimumab JAMA dermatology · 2014
    27. Alopecia Induced by Tumor Necrosis Factor-Alpha Antagonists: Description of 52 Cases and Disproportionality Analysis in a Nationwide Pharmacovigilance Database Rheumatology · 2014
    28. Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three Patients Journal of cutaneous medicine and surgery · 2012
    29. Alopecia Areata: A New Treatment Plan Clinical, cosmetic and investigational dermatology · 2011
    30. Alefacept for Alopecia Areata Archives of dermatology · 2005

    Related research 1

    1. Serum Zinc Concentration in Patients With Alopecia Areata Acta dermato-venereologica (Print) · 2023